KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Receivables (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Receivables for 16 consecutive years, with $450.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 99.96% to $450.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $450.0 through Dec 2025, down 99.96% year-over-year, with the annual reading at $450.0 for FY2025, 99.96% down from the prior year.
  • Receivables hit $450.0 in Q4 2025 for Inovio Pharmaceuticals, down from $978590.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $11.7 million in Q4 2022 to a low of $450.0 in Q4 2025.
  • Historically, Receivables has averaged $4.6 million across 5 years, with a median of $3.1 million in 2021.
  • Biggest five-year swings in Receivables: soared 3057.18% in 2024 and later crashed 99.96% in 2025.
  • Year by year, Receivables stood at $8.1 million in 2021, then soared by 45.49% to $11.7 million in 2022, then tumbled by 79.51% to $2.4 million in 2023, then plummeted by 50.15% to $1.2 million in 2024, then plummeted by 99.96% to $450.0 in 2025.
  • Business Quant data shows Receivables for INO at $450.0 in Q4 2025, $978590.0 in Q3 2025, and $840312.0 in Q2 2025.